Skip to main content
. 2021 Jul 20;373(6557):931–936. doi: 10.1126/science.abg5827

Fig. 2. Discovery of repurposed drugs that inhibit SARS-CoV-2 in human lung cells.

Fig. 2.

Of the 26 drugs that inhibited OC43 and tested against SARS-CoV-2, 20 inhibited SARS-CoV-2 replication in a dose-dependent manner, showing good concordance between OC43 and SARS-CoV-2 inhibition. A549 cells overexpressing ACE2 were pretreated with the indicated drugs for 2 hours, infected with SARS-CoV-2 (MOI 0.5), and incubated for 2 days. Cells were stained for the presence of the spike protein, and the percentage of infected cells was determined. Most of the drugs that were effective against OC43 showed similar effectivity against SARS-CoV-2; n = 3. Individual measurements are shown as semitransparent gray circles. (Note that some circles overlap.) Additional dose-response curves are shown in fig. S3.